Most people can relate to discomfort caused by reflux and heartburn, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events or just a cup of coffee with friends. More severe stages of GERD can be very painful, with difficulty in swallowing and esophageal erosions or ulcerations (esophagitis).
The Next Leap Forward
Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate, formerly known as X842, takes a new approach to provide improved management of GERD.
Built on world-leading industrial tradition, Linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. During 2021, clinical phase 1 trials were successfully completed and clinical phase II trials were initiated. Linaprazan glurate represents a new and novel mode of action with superior efficacy and pharmacokinetic profile versus PPI’s.
Last Patient Out (LPO) from the Phase II study of linaprazan glurate
On September 1st, we had LPO – Last Patient Out, from the Phase II study of linaprazan glurate. The study includes a total of 228 patients.
Gösta Hiller - A driven leader who wants to build smart teams and see people grow together
Gösta has extensive experience in leadership positions that will come in handy as Cinclus now prepares for the next step.
Peter Unge – Clinician and senior advisor with extensive experience in gastroenterology
Peter Unge's knowledge and long experience are essential assets in the clinical operations of Cinclus Pharma.
CEO Cinclus Pharma